Results 121 to 130 of about 19,271 (221)

A novel therapeutic strategy for pancreatic neoplasia using a novel RNAi platform targeting PDX-1 [PDF]

, 2011
Bi-functional shRNA (bi-shRNA), a novel RNA interference (RNAi) effector platform targeting PDX-1 utilizing a systemic DOTAP-Cholesterol delivery vehicle, was studied in three mouse models of progressive pancreatic neoplasia.
Charles Brunicardi, David Dawson, Donald Rao, Francesco DeMayo, John Nemunaitis, Kelly Stehling, Marie-Claude Gingras, Michael Norman, Nancy Templeton, Neil Senzer, Richard Gibbs, Shi-He Liu, William Fisher, Zhaohui Wang   +13 more
core   +1 more source

Severe Euglycemic Diabetic Ketoacidosis Requiring Intubation After Tirzepatide and SGLT2 Inhibitor Coadministration in a Patient With Type 1 Diabetes Mellitus From a Large Tertiary Care Centre in Karachi, Pakistan: A Case Report and Brief Review of the Literature

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Euglycemic diabetic ketoacidosis (euDKA) is an uncommon but potentially life‐threatening complication that may arise in patients treated with incretin‐based therapies or Sodium–Glucose Cotransporter‐2 (SGLT2) inhibitors. We report a 41‐year‐old female with Type 1 Diabetes Mellitus (T1DM) who developed severe euDKA after initiating tirzepatide ...
Maliha Malik, Hammad Amjad, Khadija Malik, Muddassir Syed Saleem, Shanzay Akhtar, Muslehuddin Paracha, Mobeen Abid, Nabahat Shafi, Ahmed Asad Raza, Abedin Samadi, Samar Abbas Jaffri   +10 more
wiley   +1 more source

Semaglutide versus Tirzepatide - comparison of both drugs in treatment of diabetes type 2 and weight reduction

Quality in Sport
In recent years, the popularity of drugs which were firstly introduced as treatment for diabetes type 2 has surged, because of their’s significant effect of managing the body weight especially for patients that suffer for diabetes type 2.
Arkadiusz Staroń, Patrycja Karkos, Katarzyna Kuśmierczyk, Bartłomiej Gastoł, Karolina Mikołap, Marta Kras, Marta Jurga   +6 more
doaj   +1 more source

Tirzepatide‐induced body composition changes: Implications from the SURPASS‐3 MRI substudy

Journal of Diabetes Investigation, EarlyView.
I‐Weng Yen, Hung‐Yuan Li
wiley   +1 more source

Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption

Comprehensive Physiology, Volume 16, Issue 1, February 2026.
Vildagliptin and omarigliptin, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have differential effects on bone cells. Although vildagliptin improved the bone microstructure of high‐fat diet‐fed rats, it was unable to downregulate osteoclastogenesis or the expression of key osteoclast transcripts.
Ratchaneevan Aeimlapa, Jiraporn Panmanee, Jarinthorn Teerapornpuntakit, Kannikar Wongdee, Jirawan Thongbunchoo, Nattapon Panupinthu, Saovaros Svasti, Nattayaporn Apaijai, Piangkwan Sa‐nguanmoo, Siriporn Chattipakorn, Nipon Chattipakorn, Narattaphol Charoenphandhu   +11 more
wiley   +1 more source

Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists

Turkish Journal of Endocrinology and Metabolism, 2022
Dilek Tüzün
doaj   +1 more source

Neurotensin and its receptors in the control of glucose homeostasis

Frontiers in Endocrinology, 2012
The pharmacological roles of the neuropeptide neurotensin through its three known receptors are various and complex. Neurotensin is involved in several important biological functions including analgesia and hypothermia in the central nervous system and ...
Jean eMazella, Sophie eBéraud-Dufour, Christelle eDevader, Fabienne eMassa, Thierry eCoppola   +4 more
doaj   +1 more source

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 1, February 2026.
ABSTRACT There are a number of guidelines on how to manage obesity, but inconsistencies in healthcare access, varying infrastructure, resource constraints and diverse local practices restrict their global applicability. This underscores the need for universal recommendations that address the unique challenges faced by patients and healthcare providers ...
Stefan D. Anker, Linong Ji, Tammy Kindel, Andrew J. S. Coats, Dike Ojji, Adriana Puente Barragán, Peter Rossing, Shelley Zieroth, Shaaf Ahmad, Shariq Usman, Geeta Appannah, Alison L. Bailey, Ahmed Bennis, Andrea Brandao, Javed Butler, Melanie J. Davies, Lubomira Fabryova, Yuan‐Lin Guo, Hidetaka Itoh, Uday M. Jadhav, Carel W. Le Roux, Fausto J. Pinto, Julio Rosenstock, Banshi Saboo, Hani Sabbour, Mangesh Tiwaskar, Karol E. Watson, Kwang Wei Tham, Fernando Stuardo Wyss, Walter P. Abhayaratna, William T. Abraham, Wael Al Mahmeed, Alessia Argirò, John J. Atherton, Danielle Belardo, Raquel Campuzano, Nandini Chatterjee, Marc‐André Cornier, Sarah Davies, Clemencia de Rueda Panadero, Anastase Dzudie, Ty J. Gluckman, Muhammad Shahzeb Khan, Kamlesh Khunti, Yuri Lopatin, Zhiyi Ma, Okechukwu S. Ogah, Abraham Oomman, Emilio S. Peralta Lopez, Ping Li, Paul Poirier, Julie Redfern, Giuseppe M. C. Rosano, Donna Ryan, Amit Saraf, Sameh Shaheen, Subodh Verma, Stephan von Haehling, Martha Gulati, Naveed Sattar, Jose Luis Zamorano   +60 more
wiley   +1 more source

Stem Cell Secretome Treatment Reduces Adiposity and Improves Glucose Handling During Obesity and Weight Loss in Mice

Obesity, Volume 34, Issue 2, Page 382-393, February 2026.
ABSTRACT Objective In this study, we investigated the effects of a stem cell‐derived secretome product on adiposity and tissue quality and insulin and glucose levels in obese mice and those undergoing dietary weight loss. Methods Following 16 weeks of high fat diet mice received acute (4 weeks) biweekly intramuscular injections with vehicle or ...
Zachary J. Fennel, Anu S. Kurian, Paul‐Emile Bourrant, Chad M. Skiles, Robert J. Castro, Elena M. Yee, Scott A. Greilach, Hans S. Keirstead, Gabriel Nistor, Nicole C. Berchtold, Thomas E. Lane, Micah J. Drummond   +11 more
wiley   +1 more source

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology

Journal of Diabetology
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj   +1 more source